Cover Image
Market Research Report

Global Breast Cancer Drugs Market - 2019-2026

Published by DataM Intelligence Product code 812778
Published Content info 130-180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Breast Cancer Drugs Market - 2019-2026
Published: March 1, 2019 Content info: 130-180 Pages
Description

Global Breast Cancer Drugs Market Overview

Breast cancer drugs are majorly divided into chemotherapy, hormone therapy, and targeted biological therapy. Chemotherapy is a systemic drug treatment intended to stop cancer cells from dividing and growing. Chemotherapy is often associated with unpleasant side effects since it targets all rapidly growing cells, in addition to cancer cells. Targeted/biological therapies (or immune targeted therapies) focus on blocking the actions of certain normal body proteins that allow cancer cells to grow and divide. These treatments target cancer cells, lessening toxicity and reducing side effects.

The global breast cancer drugs market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.

Market Drivers:

Increase in prevalence of breast cancer cases across the globe, the rapid surge in awareness of breast cancer among the disease population and increase in survival rate of breast cancer population are driving the global breast cancer drugs market during the forecast period.

According to the American Cancer Society in 2018, it is estimated that 266,120 new cases of invasive breast cancer will be diagnosed in women in unites states.

According to Breast Cancer organization in 2018, estimated that About 1 in 8 U.S. women (about 12%) will develop invasive breast cancer over the course of her lifetime.

Restraint:

Major factors hindering the global breast cancer drugs market during the forecast period are the side effects caused by the disease population post medication it includes early menopause, bleeding, diarrhea, and others, and high cost associated with the therapeutic treatment.

Market Segmentation

Global breast cancer drugs market is segmented by therapy type and distribution channel. By therapy type includes hormone therapy, chemotherapy, and targeted therapy, hormone therapy includes selective estrogen receptor modulator (SERM), Aromatase Inhibitors, Estrogen-receptor down-regulators (ERD), and luteinizing hormone-releasing hormone agents (LHRH). The chemotherapy segment includes adjuvant chemotherapy, neoadjuvant chemotherapy, and advanced breast cancer, and targeted therapy includes trastuzumab, trastuzumab, ado-trastuzumab emtansine, lapatinib, and neratinib. The distribution channel hospitals, ambulatory surgical centers, clinics, retail Pharmacies, and online pharmacies.

Targeted therapy dominate the global breast cancer drugs market during the forecast period due to its less side effects offered by the treatment compared to the conventional therapy and cost-effective nature. Targeted cancer therapies or drugs that block the growth and spread of cancer by interfering with specific molecules that involved in growth, progression and spread of cancer.

Global Breast Cancer Drugs Market - Geographical Analysis

The global breast cancer drugs market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

North America dominates the global breast cancer drugs market owing to rise in prevalence of breast cancer, the presence of key players and a rapid surge in extensive usage of targeted therapies across the region and it is expected remain high during the forecast period.

Presence of developed healthcare infrastructure and increased spending by the diseased population for treatment and continuous ongoing research by key players & research organizations for the development of advanced or targeted drugs is additionally contributing to the growth in North America during the forecast period.

According to American Cancer society, surveillance and health services research in 2016, approximately 50% of breast cancer diseased population were given a combination of mastectomy, radiation therapy and chemotherapy as their treatment plan by doctors.

Global Breast Cancer Drugs Market - Competitive Analysis

Recent FDA and European Union ( EU) approvals for advanced or metastatic breast cancer and new product launches by regional players are driving the global Breast Cancer Drugs market during the forecast period.

In January 2019, Hetero launches generic breast cancer treatment drug under the brand name 'Hertab' with the strength of 250g in India.

In October 2018, Eli Lilly's CDK 4 and 6 inhibitor Verzenios has been approved by the European Union for the treatment of certain metastatic breast cancers.

In July 2018, Novartis received new U.S FDA approval for Kisqali® (ribociclib for women with hormone-receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

In February 2018, Eli Lilly & co received FDA approval for expanded usage of Verzenio breast cancer drug as an initial treatment for certain women with advanced or metastatic disease.

Major market players in the breast cancer drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Abbvie, Inc, Eli Lilly and Company, Astrazeneca, Celgene Corporation, Biocon, Merck & Co, Inc, Janssen Global Services LLC, Genzyme Corporation, and others.

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents

1. GLOBAL BREAST CANCER DRUGS MARKET -SCOPE AND METHODOLOGY

  • 1.1. Research Methodology
  • 1.2. The Scope of the market

2. GLOBAL BREAST CANCER DRUGS MARKET-EXECUTIVE SUMMARY

3. INDUSTRY ANALYSIS

  • 3.1. Drivers
  • 3.2. Restraints
  • 3.3. Opportunity
  • 3.4. Regulation
  • 3.5. Supply Chain Analysis
  • 3.6. Technological Advancements
  • 3.7. Porter's Five Forces Analysis

4. GLOBAL BREAST CANCER DRUGS MARKET SEGMENTATION

  • 4.1. BY THERAPHY TYPE
    • 4.1.1. Hormone therapy
      • 4.1.1.1. SERM
      • 4.1.1.2. Aromatase Inhibitors
      • 4.1.1.3. ERD
      • 4.1.1.4. LHRH
    • 4.1.2. Chemotherapy
      • 4.1.2.1. Adjuvant Chemotherapy
      • 4.1.2.2. Neoadjuvant Chemotherapy
      • 4.1.2.3. Advanced Breast Cancer
    • 4.1.3. Targeted Therapy
      • 4.1.3.1.1. Trastuzumab
      • 4.1.3.1.2. Ado-Trastuzumab Emtansine
      • 4.1.3.1.3. Lapatinib
      • 4.1.3.1.4. Neratinib
  • 4.2. BY DISTRIBUTION CHANNEL
    • 4.2.1. Hospitals
    • 4.2.2. Ambulatory Surgical centers
    • 4.2.3. Clinics
    • 4.2.4. Retail Pharmacies
    • 4.2.5. Online Pharmacies

5. GLOBAL BREAST CANCER DRUGS MARKET - BY GEOGRAPHY

  • 5.1. Geographic Overview
  • 5.2. North America
    • 5.2.1. The U.S.
    • 5.2.2. Mexico
    • 5.2.3. Canada
  • 5.3. Europe
    • 5.3.1. Germany
    • 5.3.2. The U.K.
    • 5.3.3. France
    • 5.3.4. Italy
    • 5.3.5. Spain
    • 5.3.6. Rest of Europe
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5. Asia Pacific
    • 5.5.1. China
    • 5.5.2. India
    • 5.5.3. Japan
    • 5.5.4. Australia
    • 5.5.5. Rest of Asia Pacific
  • 5.6. Middle East and Africa

6. COMPETITIVE LANDSCAPE

  • 6.1. Competitive Scenario
  • 6.2. Heat Map Analysis
  • 6.3. Product Benchmarking

7. COMPANY PROFILES

  • 7.1. F. Hoffmann-La Roche Ltd
  • 7.2. Novartis Ag
  • 7.3. Abbvie, Inc.
  • 7.4. Eli Lilly And Company
  • 7.5. Astrazeneca
  • 7.6. Celgene Corporation
  • 7.7. Biocon
  • 7.8. Merck & Co., Inc
  • 7.9. Janssen Global Services Llc
  • 7.10. Genzyme Corporation
  • 7.11. Others

8. Key companies to watch

9. Emerging Companies

10. APPENDIX

  • 10.1. Sources
  • 10.2. List of Tables
  • 10.3. Expert Panel Validation
  • 10.4. Disclaimer
  • 10.5. Contact Us
Back to Top